1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Smart Inhalers Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Smart Inhalers Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Smart Inhalers Market Regional Analysis
6.2 Europe Smart Inhalers Market Revenue 2016-2027 (US$ Million)
6.3 Europe Smart Inhalers Market Forecast Analysis
7. Europe Smart Inhalers Market Analysis – by Product
7.1 Nebulizers and Inhalers
- 7.1.1 Overview
- 7.1.2 Nebulizers and Inhalers: Europe Smart Inhalers Market – Revenue and Forecast, 2016-2027 (US$ Million)
8. Europe Smart Inhalers Market Analysis – by Disorder
8.1 Chronic Obstructive Pulmonary Disease
- 8.1.1 Overview
- 8.1.2 Chronic Obstructive Pulmonary Disease : Europe Smart Inhalers Market – Revenue and Forecast, 2016-2027 (US$ Million)
9. Europe Smart Inhalers Market Analysis – by End User
9.1 Home-Care Settings and Hospitals & Clinics
- 9.1.1 Overview
- 9.1.2 Home-Care Settings and Hospitals & Clinics: Europe Smart Inhalers Market – Revenue and Forecast, 2016-2027 (US$ Million)
10. Europe Smart Inhalers Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Smart Inhalers Market Breakdown, by Key
Country, 2019 and 2027 (%)
- 10.2.1.1 Europe Smart Inhalers Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 UK: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.1.2 UK: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.1.3 UK: Europe Smart Inhalers Market Breakdown, by End User
- 10.2.1.2 Germany:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Germany: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.2.2 Germany: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.2.3 Germany: Europe Smart Inhalers Market Breakdown, by End User
- 10.2.1.3 France:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 France: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.3.2 France: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.3.3 France: Europe Smart Inhalers Market Breakdown, by End User
- 10.2.1.4 Russia:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.4.1 Russia: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.4.2 Russia: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.4.3 Russia: Europe Smart Inhalers Market Breakdown, by End User
- 10.2.1.5 Italy:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.5.1 Italy: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.5.2 Italy: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.5.3 Italy: Europe Smart Inhalers Market Breakdown, by End User
- 10.2.1.6 Rest of Europe:
Europe Smart Inhalers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Smart Inhalers Market Breakdown, by Product
- 10.2.1.6.2 Rest of Europe: Europe Smart Inhalers Market Breakdown, by Disorder
- 10.2.1.6.3 Rest of Europe: Europe Smart Inhalers Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 GlaxoSmithKline plc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Adherium Ltd.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Vectura Group plc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Novartis AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Findair Sp. z o. o.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Cohero Health
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Crux Product Design Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Teva Pharmaceuticals
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 3M
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Amiko Digital Health Limited
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For Europe Smart Inhalers Market
